Global Diagnostic Nuclear Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diagnostic Nuclear Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Nuclear Drugs are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
Diagnostic Nuclear Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diagnostic Nuclear Drug market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Diagnostic Nuclear Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Diagnostic Nuclear Drug introduction, etc. Diagnostic Nuclear Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Diagnostic Nuclear Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Diagnostic Nuclear Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diagnostic Nuclear Drug market is projected to reach US$ 7534.8 million in 2029, increasing from US$ 4722 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diagnostic Nuclear Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Diagnostic Nuclear Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Diagnostic Nuclear Drug introduction, etc. Diagnostic Nuclear Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Diagnostic Nuclear Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
